Claims:

1. Use of Compound I of the following formula

or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of uveal melanoma.

- 2. The use according to claim 1 wherein the uveal melanoma is a metatazing uveal melanoma.
- 3. The use according to claim 1 wherein the uveal melanoma expresses c-kit.
- 4. The use according to claim 1 wherein Compound I is in the form of the monomethanesulfonate salt.
- 5. The use according to claim 4 wherein the monomethanesulfonate salt of Compound I is in the beta crystal form.
- 6. The use according to claim 1 wherein Compound I is administered at a daily dose corresponding to 100 mg to 1000 mg of Compound I free base.
- 7. The use according to claim 6 wherein Compound I is administered once daily for a period exceeding 3 months.
- 8. A method of treating a mammal suffering from uveal melanoma which comprises administering to said mammal in need of such a treatment a dose, effective against said disease, of Compound I or a pharmaceutically acceptable salt thereof.
- 9. Use of a c-kit inhibitor or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of uveal melanoma.
- 10. Use according to claim 9 wherein the uveal melanoma is a metastazing uveal melanoma.